Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) Pseudomonas

Background: Data on the patient outcomes for newer β-lactam–β-lactamase inhibitor (BLBI) drugs compared to carbapenem-containing combination antibiotics for multidrug-resistant (MDR)–Pseudomonas aeruginosa infections are limited. Methods: This retrospective, case–control observational study was base...

Descripción completa

Detalles Bibliográficos
Autores principales: Shamsulddin, Haider, Lin, Jeffrey, Ribes, Julie, Myint, Thein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Mdr Gnr
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551578/
http://dx.doi.org/10.1017/ash.2021.134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551578/
http://dx.doi.org/10.1017/ash.2021.134

Ejemplares similares